What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
SaiyanMed Research Grade Retatrutide Triple incretin receptor agonist (GIP / GLP-1 / glucagon) LY3437943 Research-grade Retatrutide (LY3437943) is a synthetic 39-amino-acid triple-receptor agonist supplied for laboratory study of incretin signaling, energy-expenditure mechanisms, and metabolic research models
Retinol, acids and vitamin C together on unprepared skin can cause irritation, so introduce them slowly
When it comes to two of the most popular wellness staplescollagen and glutathionethe question of timing is one we hear often
described a patient with retrocaval MMNST who experienced decreased pain and disease stabilization with pembrolizumab prior to resection [35]
Injection site reactions
